2024
Real-world infection risk in multiple sclerosis patients on long-term immunomodulatory treatments
Lambert C, Hussain T, Peters J, Longbrake E. Real-world infection risk in multiple sclerosis patients on long-term immunomodulatory treatments. Multiple Sclerosis And Related Disorders 2024, 94: 106236. PMID: 39755026, PMCID: PMC11869388, DOI: 10.1016/j.msard.2024.106236.Peer-Reviewed Original ResearchConceptsCharlson Comorbidity IndexAnti-CD20 medicationsDisease-modifying treatmentsDMT useS1P modulatorsImmunomodulatory treatmentImmune cellsSevere infectionsMultiple sclerosisLong-term immunomodulatory treatmentReal-life practice patternsTreatment durationInfection rateSelection of patientsClinical selection of patientsDeplete immune cellsObservational cohort studyBody mass indexSevere infection rateAnalyzed medical recordsIncreased infection riskInfection riskDisease modifying therapiesMultiple sclerosis patientsImmune subsets
2022
High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis
Freeman L, Longbrake E, Coyle P, Hendin B, Vollmer T. High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis. CNS Drugs 2022, 36: 1285-1299. PMID: 36350491, PMCID: PMC9645316, DOI: 10.1007/s40263-022-00965-7.Peer-Reviewed Original ResearchMeSH KeywordsAlemtuzumabHumansImmunologic FactorsMultiple SclerosisMultiple Sclerosis, Relapsing-RemittingNatalizumabConceptsRelapsing-remitting multiple sclerosisHigh-efficacy therapiesMultiple sclerosisClinical benefitEarly treatmentRecent international consensus guidelinesLong-term clinical outcomesAvailable treatment optionsInternational consensus guidelinesTreatment-naïve individualsMechanism of actionDMT optionsMS careDisease courseClinical outcomesConsensus guidelinesTherapy optionsTreatment optionsNeurological damageTreatment strategiesEscalation approachClinical practiceUS FoodDrug AdministrationPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply